Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-312023-07-01true4truetruetruetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falsefalseProvision of manufacturing services3truetrue 02826839 2023-07-01 2023-12-31 02826839 2022-07-01 2023-06-30 02826839 2023-12-31 02826839 2023-06-30 02826839 2022-07-01 02826839 1 2023-07-01 2023-12-31 02826839 d:Director1 2023-07-01 2023-12-31 02826839 c:PlantMachinery 2023-07-01 2023-12-31 02826839 c:PlantMachinery 2023-12-31 02826839 c:PlantMachinery 2023-06-30 02826839 c:PlantMachinery c:OwnedOrFreeholdAssets 2023-07-01 2023-12-31 02826839 c:OtherPropertyPlantEquipment 2023-07-01 2023-12-31 02826839 c:OtherPropertyPlantEquipment 2023-12-31 02826839 c:OtherPropertyPlantEquipment 2023-06-30 02826839 c:OtherPropertyPlantEquipment c:OwnedOrFreeholdAssets 2023-07-01 2023-12-31 02826839 c:OwnedOrFreeholdAssets 2023-07-01 2023-12-31 02826839 c:CurrentFinancialInstruments 2023-12-31 02826839 c:CurrentFinancialInstruments 2023-06-30 02826839 c:Non-currentFinancialInstruments 2023-12-31 02826839 c:Non-currentFinancialInstruments 2023-06-30 02826839 c:CurrentFinancialInstruments c:WithinOneYear 2023-12-31 02826839 c:CurrentFinancialInstruments c:WithinOneYear 2023-06-30 02826839 c:Non-currentFinancialInstruments c:AfterOneYear 2023-12-31 02826839 c:Non-currentFinancialInstruments c:AfterOneYear 2023-06-30 02826839 c:Non-currentFinancialInstruments c:BetweenOneTwoYears 2023-12-31 02826839 c:Non-currentFinancialInstruments c:BetweenOneTwoYears 2023-06-30 02826839 c:ShareCapital 2023-07-01 2023-12-31 02826839 c:ShareCapital 2023-12-31 02826839 c:ShareCapital 2022-07-01 2023-06-30 02826839 c:ShareCapital 2023-06-30 02826839 c:ShareCapital 2022-07-01 02826839 c:RetainedEarningsAccumulatedLosses 2023-07-01 2023-12-31 02826839 c:RetainedEarningsAccumulatedLosses 2023-12-31 02826839 c:RetainedEarningsAccumulatedLosses 2022-07-01 2023-06-30 02826839 c:RetainedEarningsAccumulatedLosses 2023-06-30 02826839 c:RetainedEarningsAccumulatedLosses 2022-07-01 02826839 c:AcceleratedTaxDepreciationDeferredTax 2023-12-31 02826839 c:AcceleratedTaxDepreciationDeferredTax 2023-06-30 02826839 c:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-07-01 2023-12-31 02826839 c:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-12-31 02826839 d:OrdinaryShareClass1 2023-07-01 2023-12-31 02826839 d:OrdinaryShareClass1 2023-12-31 02826839 d:OrdinaryShareClass1 2023-06-30 02826839 d:FRS102 2023-07-01 2023-12-31 02826839 d:AuditExempt-NoAccountantsReport 2023-07-01 2023-12-31 02826839 d:FullAccounts 2023-07-01 2023-12-31 02826839 d:PrivateLimitedCompanyLtd 2023-07-01 2023-12-31 02826839 e:PoundSterling 2023-07-01 2023-12-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number:02826839





AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023


 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
REGISTERED NUMBER: 02826839

BALANCE SHEET
AS AT 31 DECEMBER 2023

31 December
30 June
2023
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
17,443
12,699

  
17,443
12,699

Current assets
  

Stocks
 5 
89,485
111,407

Debtors: amounts falling due within one year
 6 
60,813
176,446

Cash at bank and in hand
 7 
59,363
9,053

  
209,661
296,906

Creditors: amounts falling due within one year
 8 
(484,114)
(210,739)

Net current (liabilities)/assets
  
 
 
(274,453)
 
 
86,167

Total assets less current liabilities
  
(257,010)
98,866

Creditors: amounts falling due after more than one year
 9 
-
(21,107)

Provisions for liabilities
  

Other provisions
 12 
(70,000)
-

  
 
 
(70,000)
 
 
-

Net (liabilities)/assets
  
(327,010)
77,759


Capital and reserves
  

Called up share capital 
 13 
100
100

Profit and loss account
  
(327,110)
77,659

  
(327,010)
77,759


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the 6 month period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.
Page 1

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
REGISTERED NUMBER: 02826839

BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023


The financial statements were approved and authorised for issue by the board and were signed on its behalf on 17 September 2024.




A Crawley
Director

The notes on pages 4 to 14 form part of these financial statements.

Page 2

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

STATEMENT OF CHANGES IN EQUITY
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 July 2023
100
77,659
77,759


Comprehensive income for the 6 month period

Loss for the 6 month period
-
(404,769)
(404,769)
Total comprehensive income for the 6 month period
-
(404,769)
(404,769)


At 31 December 2023
100
(327,110)
(327,010)


The notes on pages 4 to 14 form part of these financial statements.


STATEMENT OF CHANGES IN EQUITY
FOR THE 6 MONTH PERIOD ENDED 30 JUNE 2023


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 July 2022
100
162,406
162,506


Comprehensive income for the year

Loss for the year
-
(84,747)
(84,747)
Total comprehensive income for the year
-
(84,747)
(84,747)


At 30 June 2023
100
77,659
77,759


The notes on pages 4 to 14 form part of these financial statements.

Page 3

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

1.


General information

Amber Therapeutics Limited (formerly Finetech Medical Limited) is a private company, limited by shares, registered in England and Wales. The Company's registered office address is 178-180 Hotwell Road, Bristol, BS8 4RP.
The principal activity of the Company is the manufacture of bladder control devices. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Amber Therapeutics Ltd as at 31 December 2023 and these financial statements may be obtained from Cannon Place, 78 Cannon Street, London, EC4N 6AF.

Page 4

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.3

Going concern

In considering the appropriate basis on which to prepare the financial statements, the Directors are required to consider whether the Company can continue in operational existence for the foreseeable future.
The Company is part of a group headed by Amber Therapeutics Holdings Limited (formerly Amber Therapeutics Ltd) which has confirmed that it will support the Company. Following the year end, the Group issued convertible loan notes of £4,000,000 on 11 March 2024, bringing the total convertible loan notes balance to £10,900,000. In addition, following the year end the Group successfully signed a Series A Fundraise for a total of £80.9m of which £70m will be received in three tranches, and £10.9m relates to the conversion of convertible loan notes held by Amber Therapeutics Holdings Limited. Tranche 1 has been successfully completed with Amber Therapeutics Holdings Limited issuing 3,926,701 Series A shares for a total consideration of $18,567,259 and £146,199. On completion of Tranche 1, the convertible loan notes of £10,900,000 converted into 1,047,121 Series A shares and 2,257,853 Series A 1 shares at par. The Directors are, therefore,of the opinion that the Group and, therefore, the Company has adequate resources to continue in operational existence for at least 12 months from the date of this report. The Directors, therefore, continue to adopt the going concern basis of accounting in preparing the financial statements.

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.6

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 5

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.8

Current and deferred taxation

The tax expense for the 6 month period comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 
2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 6

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.9
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
10%
Straight-line
Leasehold improvements
-
10%
Straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.10

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.11

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.12

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.14

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

Page 7

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.15

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each reporting date. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial instruments

Page 8

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.15
Financial instruments (continued)

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.


3.


Employees

The average monthly number of employees, including the directors, during the 6 month period ended 31 December 2023 was 3 (year to 30 June 2023 4).


4.


Tangible fixed assets







Plant and machinery
Leasehold improvements
Total

£
£
£



Cost or valuation


At 1 July 2023
116,963
-
116,963


Additions
4,721
2,309
7,030



At 31 December 2023

121,684
2,309
123,993



Depreciation


At 1 July 2023
104,264
-
104,264


Charge for the 6 month period on owned assets
2,270
16
2,286



At 31 December 2023

106,534
16
106,550



Net book value



At 31 December 2023
15,150
2,293
17,443

Page 9

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

5.


Stocks

31 December
30 June
2023
2023
£
£

Stock
89,485
111,407

89,485
111,407


Page 10

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

6.


Debtors

31 December
30 June
2023
2023
£
£


Trade debtors
39,272
12,945

Amounts owed by group undertakings
2,828
2,828

Other debtors
9,585
9,240

Prepayments and accrued income
9,128
8,315

Deferred taxation
-
143,118

60,813
176,446


Amounts owed by group undertakings are non-interest bearing and repayable on demand. 


7.


Cash and cash equivalents

31 December
30 June
2023
2023
£
£

Cash at bank and in hand
59,363
9,053

59,363
9,053



8.


Creditors: Amounts falling due within one year

31 December
30 June
2023
2023
£
£

Bank loans
26,615
10,069

Trade creditors
18,340
46,089

Amounts owed to group undertakings
381,398
121,398

Other taxation and social security
10,677
13,570

Other creditors
418
701

Accruals and deferred income
46,666
18,912

484,114
210,739


Amounts owed to group undertakings are non-interest bearing and repayable on demand. 

Page 11

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

9.


Creditors: Amounts falling due after more than one year

31 December
30 June
2023
2023
£
£

Bank loans
-
21,107

-
21,107



10.


Loans


Analysis of the maturity of loans is given below:


31 December
30 June
2023
2023
£
£

Amounts falling due within one year

Bank loans
26,615
10,069


26,615
10,069

Amounts falling due 1-2 years

Bank loans
-
21,107


-
21,107



26,615
31,176



11.


Deferred taxation






2023


£






At beginning of year
143,118


Utilised in year
(143,118)



At end of year
-

Page 12

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023
 
11.Deferred taxation (continued)

31 December
30 June
2023
2023
£
£


Accelerated capital allowances
-
143,118

-
143,118


12.


Provisions






Dilapidation provision

£





Charged to profit or loss
70,000



At 31 December 2023
70,000

The dilapidation provision relates to an estimate of costs for restoration, repair and redecoration of the Company's leased premises at the termination of the leases in accordance with the terms of the lease agreements. 


13.


Share capital

31 December
30 June
2023
2023
£
£
Allotted, called up and fully paid



100 (2023 - 100) Ordinary shares of £1.00 each
100
100



14.


Related party transactions

The Company has taken the exemption under Section 33 of FRS 102 not to disclose transactions with wholly owned group companies. 


15.


Post balance sheet events

After the period end, the Company acquired the trade and assets of Bioinduction Limited and Amber Therapeutics Holdings Limited (formerly Amber Therapeutics Ltd), two fellow group companies. The Company also changed its name to Amber Therapeutics Limited. 

Page 13

 
AMBER THERAPEUTICS LIMITED (FORMERLY FINETECH MEDICAL LIMITED)
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE 6 MONTH PERIOD ENDED 31 DECEMBER 2023

16.


Controlling party

During the period, the ultimate controlling party was Amber Therapeutics Holdings Limited (formerly Amber Therapeutics Ltd) by virtue of its 100% shareholding in the Company. The consolidated statements of Amber Therapeutics Holdings Limited (formerly Amber Therapeutics Ltd) are publically available from Cannon Place, 78 Cannon Street, London, EC4N 6AF.

Page 14